SPY299.08+3.64 1.23%
DIA250.25+5.37 2.19%
IXIC9,340.22+15.63 0.17%

Raymond James Maintains Outperform on Galmed Pharmaceuticals, Lowers Price Target to $20

Raymond James maintains Galmed Pharmaceuticals (NASDAQ:GLMD) with a Outperform and lowers the price target from $25 to $20.

Benzinga · 05/15/2020 12:31

Raymond James maintains Galmed Pharmaceuticals (NASDAQ:GLMD) with a Outperform and lowers the price target from $25 to $20.